Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Verastem Oncology < Previous 1 2 Next > Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates August 08, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer July 29, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants July 23, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants July 23, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics July 12, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 08, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes July 01, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer May 24, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer May 23, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates May 09, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference May 07, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer April 18, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer March 18, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates March 14, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs March 11, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer March 05, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 March 05, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers January 29, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) January 18, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference January 11, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics December 18, 2023 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer December 13, 2023 From Verastem Oncology Via Business Wire Tickers VSTM New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach November 13, 2023 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 08, 2023 From Verastem Oncology Via Business Wire Tickers VSTM First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer November 07, 2023 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population November 06, 2023 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Strengthens Executive Leadership Team with Key Appointments October 26, 2023 From Verastem Oncology Via Business Wire Tickers VSTM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 18, 2023 From Verastem Oncology Via Business Wire Tickers VSTM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.